Navigation Links
New screening approach uncovers potential alternative drug therapies for neuroblastoma
Date:5/23/2013

Nearly two-thirds of patients with high-risk neuroblastoma a common tumor that forms in the nerve cells of childrencannot be cured using tumor-killing cancer drugs. A study published by Cell Press in the May 23 issue of Chemistry & Biology reveals a new genomic approach to screen for compounds that could inhibit tumor growth by causing cancer cells to differentiate, or convert from immature cells to more specialized cell types. Using this screening method, the researchers identified a compound that causes neuroblastoma cells to differentiate, uncovering a promising new treatment strategy for this highly malignant pediatric cancer.

"New treatment approaches are very much needed for children with high-risk childhood cancers; that is, those that are metastatic at diagnosis and likely to recur," says senior study author Kimberly Stegmaier of the Dana-Farber/Children's Hospital Cancer Center and the Broad Institute of the Massachusetts Institute of Technology and Harvard University. "By focusing on an alternative strategy to treating neuroblastoma tumors, we identified a compound class that in early testing in neuroblastoma cells in the laboratory shows promise for treating children with this disease."

Beyond the standard approach of using drugs that kill tumor cells, another promising strategy is to identify compounds that promote differentiation, which causes tumor cells to stop dividing and growing. But the benefits of differentiation therapy had not been fully explored.

To address this need, Stegmaier and her team developed a method to screen small molecules for their ability to trigger differentiation in neuroblastoma cells. First, they treated these cells with drugs known to induce differentiation and looked for accompanying changes in the activity levels of genes. They found that 59 genes showed changes related to differentiation. Using this genetic signature for differentiation, they then screened nearly 2,000 small molecules and identified one compound that strongly promoted differentiation in neuroblastoma cells, especially when combined with a drug already approved to treat this type of cancer.

The newly identified compound works by selectively inhibiting a subset of gene-regulating proteins called histone deacetylases (HDACs). "This work supports the need to develop selective HDAC inhibitors for clinical application and, more broadly, illuminates the power of integrating signature-based screening with new approaches to chemical synthesis to provide novel biological insights into human disease," Stegmaier says.


'/>"/>

Contact: Mary Beth O'Leary
moleary@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Genetic screening could reveal hidden high risk for coronary heart disease
2. Pulse Oximetry Screening for Newborns a Reality in North Carolina
3. Bay Area Hospital Selects BESLER Consulting’s BVerified (SM)- Screening and Verification Solution
4. Memorial Hospital Wellness Vehicle to Offer Health Screenings at Affordable Assisted Living Community in St. Louis Metro East
5. Water’s Edge Dermatology Offers Complimentary Skin Cancer Screenings in May for Skin Cancer Awareness Month
6. Outsourced Ion Channel Primary Screening Trends & 2015 Forecast in New Market Research Report at ReportsnReports.com
7. PreCheck, Inc. Achieves Background Screening Credentialing Council Accreditation
8. PharmaSmart® and Kinney Drugs Partner up to Unveil Newest Advancement in Pharmacy-Based Biometric Screening and Mobile Interoperability
9. New Guidelines Suggest HIV Screening for All Adults
10. Personalizing prostate cancer screenings
11. Research finds targeted screening for hepatitis C is cost-effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... ... July 28, 2017 , ... For over 20 years Sealy Baby ... for their babies. We take tremendous pride in using some of nature’s best materials ... classic, natural, and innovative crib mattresses and crib bedding for ...
(Date:7/28/2017)... ... July 28, 2017 , ... ... financial planning assistance to families and business owners in and around the greater ... held in honor of the Make-A-Wish Foundation. , The Make-A-Wish Foundation is an ...
(Date:7/28/2017)... , ... July 28, 2017 , ... ... Center for Shamanic Healing and Spiritual Awakening, is proud to announce the ... 2017. , Those interested in learning more about the mystical world of ...
(Date:7/27/2017)... ... ... Georgia Urology , the largest urology practice in the Southeastern United States, ... patients in the Braselton and Gainesville offices. The Braselton office is located at 7316 ... Wednesdays, and Fridays. The Gainesville office (675 White Sulphur Road, Suite 180, Gainesville), located ...
(Date:7/27/2017)... ... July 27, 2017 , ... Trusted dentist, speaker and ... sleep apnea in Wayne, NJ to receive custom treatment at his practice ... apnea with the use of custom-crafted oral appliances. Highly-trained in using the latest ...
Breaking Medicine News(10 mins):
(Date:7/26/2017)... Medical Aesthetics, a leading medical aesthetic clinic in Singapore ... several skin conditions from the inside. The natural process ... The skin becomes more transparent due to the thinning of the ... from the sun contributes to aging skin, causing age spots and ... ...
(Date:7/25/2017)... July 25, 2017  Debbie,s Dream Foundation: Curing Stomach Cancer (DDF) is excited ... 25, 2017 at the Bonaventure Resort & Spa in Weston, Florida ... ... President Debbie Zelman, and Luncheon Committee Co-chair Sabrina Kurzman. ... Aura Morales-Guzman, Angela Perez, ...
(Date:7/21/2017)... Md. and RESEARCH TRIANGLE PARK, ... Therapeutics Corporation (NASDAQ: UTHR ) announced today ... results before the market opens on Thursday, July 27, ... will host a teleconference on Thursday, July 27, 2017, ... by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  A ...
Breaking Medicine Technology: